Emily Jashinsky

among breast cancer patients a 43% lower risk, liver cancer patients seeing a 38% lower risk, and colorectal cancer patients with a 31% lower risk.

Researchers also finding lower rates of spread in prostate, pancreatic, and kidney cancer among patients taking GLP-1s, but those differences were not large enough to be considered statistically significant.

Tumor biology may offer one clue.

With better outcomes seen in patients whose tumors had higher levels of GLP-1 receptors,

the proteins that allow cells to respond to GLP-1 hormones and medications.

Lead study author Dr. Mark Orland telling the American Society of Clinical Oncology Daily News, quote, these results deserve cautious optimism.

For patients managing both diabetes and cancer, the possibility that their anti-diabetic medication may also be working in their favor is an encouraging finding.

The study was retrospective, meaning it cannot prove the GLP-1 drugs directly caused the improved outcomes.

The results could have been influenced by other factors, including patients' underlying health conditions, weight loss, and broader metabolic improvements after starting the drugs.

Dr. Orland noting the next step would be a randomized, controlled trial, where GLP-1 use is assigned by researchers rather than simply observed in patient records.

After Artemis II sent astronauts farther from Earth than any humans before them, NASA now turning to the next step in its Moon to Mars plan, a new wave of lunar missions meant to test the landers, rovers, habitats, and power systems that could one day support a mission to Mars.

On Tuesday, NASA Administrator Jared Isaacman and other top officials awarding the latest round of lucrative contracts to the U.S.

companies set to provide the equipment needed to pull off this historic achievement.

Isaacman describing the brutal reality of the task ahead.

The contracts totaling in the hundreds of millions of dollars, marking the first phase in NASA's projected $20 billion investment over the next seven years to establish a permanent moon base.

Jeff Bezos' Blue Origin winning a $188 million contract, with a possible extension worth another $280.4 million to deliver NASA equipment to the moon's south pole as soon as fall 2026.

Companies Astrolab and Lunar Outpost awarded $219 million and $220 million, respectively, to develop and deliver NASA's first lunar terrain vehicles, giving astronauts and robotic missions the ability to move across the moon's surface by 2028.

The contracts tied to three missions, Moonbase 1, 2, and 3, all targeted for launch this year, each aimed at testing a different piece of NASA's long-term plan for a permanent lunar presence.

More from Isaacman.

NASA planning to announce more than a dozen missions this year, all in preparation to return astronauts to the moon.